American Society of Hematology

SHERPA: Blue

People

  1. Goldberg
    Goldberg
  2. Tallman
    Tallman
  3. Famulare
    Famulare
  4. Stein
    Stein
  5. Levine
    Levine
  6. Derkach
    Derkach
  7. Roshal
    Roshal
  8. Cai
    Cai
  9. Xiao
    Xiao
  10. Geyer
    Geyer

Groups

  1. Adult Leukemia (68)
  2. Center for Hematologic Malignancies (68)
  3. Department of Medicine (68)
  4. Hematologic Malignancies, Division of (68)
  5. Hematology-Oncology Fellows (68)
  6. Weinberg Fellows (68)
  7. Epidemiology and Biostatistics (22)
  8. Biostatistics Service (19)
  9. Department of Pathology and Laboratory Medicine (17)
  10. GME, Medicine (16)
Search Within
  1. "Aaron Goldberg"
Formats
  1. Meeting Abstract (60)
  2. Journal Article (7)
  3. Research Letter (1)
Groups
  1. Adult Leukemia (68)
  2. Center for Hematologic Malignancies (68)
  3. Department of Medicine (68)
  4. Hematologic Malignancies, Division of (68)
  5. Hematology-Oncology Fellows (68)
  6. Weinberg Fellows (68)

More Groups

People
  1. Aaron Goldberg (68)
  2. Martin Tallman (29)
  3. Christopher Famulare (26)
  4. Eytan Stein (23)
  5. Ross Levine (14)
  6. Jacob Glass (13)

More People

Years
  1. 2024 (13)
  2. 2023 (11)
  3. 2022 (7)
  4. 2021 (10)
  5. 2020 (9)
  6. 2019 (6)

More Years

Publications
  1. Blood (63)
  2. Blood Advances (5)

Results (68)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • A multi-site break through cancer trial: Phase II study investigating dual inhibition of BCL2 and menin in AML MRD using the combination of venetoclax and revumenib (trial in progress)
    Meeting Abstract

    Issa, G. C.; Ambinder, A. J.; Xiao, W.; Manalis, S.; Shalek, A. K.; Gondek, L. P.; Kentsis, A.; Short, N. J.; Daver, N.; Ning, J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Results from the Great Britain AML real world evidence (ARC) initiative - A centre-based chart review study to assess treatment outcomes of venetoclax for the treatment of acute myeloid leukemia
    Meeting Abstract

    O'Nions, J.; Errico, G.; Floro, L.; Murthy, V.; Sweeney, C.; Kaur, H.; Mohite, U.; Ayto, R.; Alvares, C.; Goldberg, A. D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • HMA/VEN treatment modifications and associated outcomes in IDH-mutant AML
    Meeting Abstract

    Chin, K. K.; Derkach, A.; Famulare, C.; Gupta, G.; Borge, P.; Geyer, M. B.; Goldberg, A. D.; Haque, T.; Park, J. H.; Roeker, L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Venetoclax-based therapy versus intensive chemotherapy followed by allogeneic-stem cell transplantation for high-risk elderly acute myeloid leukemia
    Meeting Abstract

    Iat, A.; Bewersdorf, J. P.; Gilhodes, J.; Liu, Y.; Shallis, R. M.; Boussi, L.; Zucenka, A.; Bystrom, R. P.; Deangelo, D. J.; Berton, G.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Minimal residual disease (MRD)-adapted duration of front-line venetoclax and obinutuzumab treatment for fit patients with chronic lymphocytic leukemia (CLL)
    Meeting Abstract

    Roeker, L.; Mato, A. R.; Zelenetz, A. D.; Park, J. H.; Geyer, M. B.; Derkach, A.; Nemirovsky, D.; Islam, P.; Falchi, L.; Palomba, M. L.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Phase II study of longitudinal geriatric assessment with risk-adapted interventions to reduce non-relapse mortality in allogeneic hematopoietic cell transplantation for older patients with advanced myeloid malignancies
    Meeting Abstract

    Lin, R. J.; Kim, S. J.; Brown, S.; Hanley, D. M.; Engstler, D. E.; Politikos, I.; Gyurkocza, B.; Tamari, R.; Papadopoulos, E. B.; Saldia, A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Cross-talk between leukemic blasts and T cells drives targetable T cell dysfunction in the AML tumor microenvironment
    Meeting Abstract

    DeWolf, S.; Ceglia, N.; Zatzman, M.; Gipson, B.; Elhanati, Y.; Katsamakis, Z.; Lees, H.; Weis, K.; Yepes, G.; Oliveira, B.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Assessing role of comorbidities in treatment selection for older patients with acute myeloid leukemia
    Meeting Abstract

    Grenet, J.; Easwar, N.; Jain, A. G.; Burkart, M.; Ma, X.; Christos, P.; Ritchie, E. K.; Samuel, M.; Kaner, J. D.; Canaani, J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • The prognostic and predictive value of RUNX1 mutations in newly diagnosed acute myeloid leukemia - An international multicenter cohort study
    Meeting Abstract

    Bystrom, R. P.; Bewersdorf, J. P.; Liu, Y.; Schaefer, E. J.; Shallis, R. M.; Boussi, L.; Zucenka, A.; Garciaz, S.; Aguirre, L. E.; DeAngelo, D. J.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Outcomes with HMA plus venetoclax vs intensive chemotherapy in AML patients with chromosome 5 and 7 abnormalities
    Meeting Abstract

    Boussi, L.; Bewersdorf, J. P.; Liu, Y.; Shallis, R. M.; Aguirre, L. E.; Zucenka, A.; Garciaz, S.; Bystrom, R. P.; DeAngelo, D. J.; Stone, R. M.; more...
    Blood (2024)

    Fulltext@MSK | Save